does tirzepatide cause breast cancer Could weight loss medication prevent recurrence? Highlighting 3 ongoing clinical trials

India is the largest provider of generic drugs globally

Die-off symptoms can be a more intense version of an infection like a cold or other virus

Clinical Trials - Key findings Type 2 diabetes (40 weeks): HbA1c 1.241.48% (vs 0.41% placebo) Weight loss 4.57.6% (vs 1.7% placebo) Obesity without diabetes (72 weeks): Mean weight loss 11.2% 54.6% achieved 10% weight loss Improved cardiometabolic markers Efficacy similar to semaglutide/liraglutide (slightly less than tirzepatide) Safety: GI effects most common (during dose escalation) Low discontinuation rates No major hypoglycemia, hepatic, or CV safety signals so far Orforglipron combines oral convenience + GLP-1level efficacy, with the potential to improve access, adherence, and long-term outcomes in diabetes and obesity management

Dehydration significantly worsens nausea

Physicians typically administer Epitalon through subcutaneous injections based on a personalized treatment protocol